Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmesis InternationalSGX:BFK 31 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates SGX:BFK with a GF Score™ of 31/100 and a GF Value™ of S$0.09 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 684 Drug Manufacturers companies, Pharmesis International ranks worse than 146198.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Pharmesis International's
Operating Income
for the
six
months ended in Dec. 2025 was S$-0.76 Mil. Pharmesis International's Interest Expense for the
six
months ended in Dec. 2025 was S$-0.06 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Pharmesis International's Interest Coverage or its related term are showing as below:
SGX:BFK's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.765 * Ranked among companies with meaningful Interest Coverage only.
Pharmesis International (SGX:BFK) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Pharmesis International Interest Coverage Related Terms
Pharmesis International Interest Coverage Historical Data
* Premium members only.
The historical data trend for Pharmesis International's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SGX:BFK vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmesis International Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Pharmesis International's Interest Coverage falls into.
Pharmesis International Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Pharmesis International did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Pharmesis International (SGX:BFK) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharmesis International and its competitors. According to the industry distribution chart, Pharmesis International ranks #999999 out of 684 companies in the Drug Manufacturers industry.
Is Pharmesis International's Interest Coverage too high?
Pharmesis International's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Pharmesis International ranks #999999 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Pharmesis International ranks #999999 out of 684 companies for Interest Coverage. This places Pharmesis International in the lower half of its industry. The industry median Interest Coverage is 12.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharmesis International and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmesis International's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Pharmesis International's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued.
The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09.
GuruFocus considers Pharmesis International to be Modestly Overvalued.
Key valuation signals for SGX:BFK:
Interest Coverage: 0 (At Loss)
GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score
Get the complete analysis for SGX:BFK
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
